Print Email Facebook Twitter Comparative effects of a contraceptive vaginal ring delivering a nonandrogenic progestin and continuous ethinyl estradiol and a combined oral contraceptive containing levonorgestrel on hemostasis variables Title Comparative effects of a contraceptive vaginal ring delivering a nonandrogenic progestin and continuous ethinyl estradiol and a combined oral contraceptive containing levonorgestrel on hemostasis variables Author Rad, M. Kluft, C. Ménard, J. Burggraaf, J. de Kam, M.L. Meijer, P. Sivin, I. Sitruk-Ware, R.L. TNO Kwaliteit van Leven Publication year 2006 Abstract Objective: This study aimed to compare the effects on hemostasis variables of a contraceptive vaginal ring with those of an oral contraceptive. Study design: Twenty-three and 22 healthy premenopausal women were randomized to the contraceptive vaginal ring (150 μg Nestorone and 15 μg ethinyl estradiol) or Stediril 30 during 3 cycles. Analysis of covariance was performed with baseline values as covariate. Results: The contraceptive vaginal ring changed most hemostasis variables similarly but raised (95% confidence intervals of percent treatment differences) Factor VIIt (28% to 49%), extrinsic activated protein C resistance (14% to 65%), and sex hormone-binding globulin (117% to 210%) and lowered Protein S (-32% to -16%) and the global activated partial thromboplastin time-based activated protein C resistance (-12% to -2%) more than the oral contraceptive. Conclusion: The contraceptive vaginal ring affected some measured hemostasis variables and sex hormone-binding globulin differently from the oral contraceptive, most likely because of difference in androgenicity of the progestins. The results suggest that the contraindications for oral contraceptive use would also apply to the tested contraceptive vaginal ring. © 2006 Mosby, Inc. All rights reserved. Chemicals / CAS: blood clotting factor 7, 9001-25-6; elcometrine, 7759-35-5; ethinylestradiol plus norgestrel, 8056-51-7; ethinylestradiol, 57-63-6; levonorgestrel, 797-63-7; Blood Coagulation Factors; Contraceptive Agents, Female; Contraceptives, Oral, Combined; Estrogens; Ethinyl Estradiol, 57-63-6; Ethinyl Estradiol-Norgestrel Combination, 8056-51-7; Norprogesterones; Plasminogen, 9001-91-6; Protein C; Sex Hormone-Binding Globulin; ST 1435, 7759-35-5 Subject BiologyBiomedical ResearchCoagulationContraceptive vaginal ringNestoroneOral contraceptivesVenous thromboembolismblood clotting factor 7elcometrineethinylestradiolethinylestradiol plus norgestrelgestagenlevonorgestreloral contraceptive agentprotein Sactivated protein C resistanceanalysis of varianceconfidence intervalcontraceptiondrug effecthemostasispartial thromboplastin timevagina ringvaginal deliveryActivated Protein C ResistanceAdolescentAdultBlood Coagulation FactorsContraceptive Agents, FemaleContraceptive Devices, FemaleContraceptives, Oral, CombinedEstrogensEthinyl EstradiolEthinyl Estradiol-Norgestrel CombinationFemaleFibrinolysisHumansImmunoradiometric AssayNorprogesteronesPlasminogenProtein CSex Hormone-Binding Globulin To reference this document use: http://resolver.tudelft.nl/uuid:94831182-47a5-4d64-961d-be38855d18a4 DOI https://doi.org/10.1016/j.ajog.2005.12.007 TNO identifier 239344 ISSN 0002-9378 Source American Journal of Obstetrics and Gynecology, 195 (1), 72-77 Document type article Files To receive the publication files, please send an e-mail request to TNO Library.